Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eplerenone. Pharmacia.

Danny Liew1, Jennifer Martin, Henry Krum

  • 1National Health and Medical Research Council, Department of Epidemiology, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia. danny.liew@med.monash.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|May 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can routinely collected electronic medical record (EMR) data support hospital resource allocation? A retrospective analysis of 332,711 presentations to a public quaternary teaching hospital in South Australia (2020-2025).

BMC health services research·2026
Same author

Trajectories of quality of life, anxiety and depressive symptomatology, and health-related work productivity after first seizure events.

Epilepsia open·2026
Same author

The evolution of cancer therapies and their Implications for health technology assessment in Australia.

Cost effectiveness and resource allocation : C/E·2026
Same author

Mortality, morbidity and healthcare costs of short-term high temperatures and heatwaves exposure in older populations: a global systematic review and meta-analysis.

Environment international·2026
Same author

Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study.

BMJ open·2026
Same author

Predicting the Emergency Department Patient Journey Using a Machine Learning Approach.

JMIR AI·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Eplerenone, an aldosterone receptor antagonist, shows promise for treating congestive heart failure. Pharmacia Corp plans to submit new data for this cardiovascular drug in early 2003.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Aldosterone receptor antagonists are crucial in managing cardiovascular diseases.
  • Pharmacia Corp is investigating eplerenone for heart failure and hypertension.

Purpose of the Study:

  • To evaluate eplerenone as a treatment for congestive heart failure.
  • To support a supplemental New Drug Application (NDA) for heart failure.

Main Methods:

  • Phase III clinical trial of eplerenone.
  • Analysis of positive trial results.

Main Results:

  • Positive outcomes observed in the phase III clinical trial for congestive heart failure.
  • Eplerenone is already registered for treating systemic hypertension.

Related Experiment Videos

Conclusions:

  • Eplerenone demonstrates potential efficacy in treating congestive heart failure.
  • Further regulatory submission for heart failure is planned based on robust clinical data.